Product Details
| Product Name:
Lagociclovir |
CAS No.:
92562-88-4 |
| Purity:
99% |
Supply Ability:
10g |
| Release date:
2024/11/19 |
Product Introduction
Bioactivity
| Name | Lagociclovir |
| Description | Lagociclovir (MIV-210), a nucleoside analogue, is an antiviral compound available for the treatment of HBV82 that inhibits the replication of wild-type hepatitis B virus (HBV) in human hepatocellular carcinoma cell lines that permanently express HBV. |
| In vitro | Lagociclovir (FLG) (6 days) demonstrated inhibitory activity against 3TC-R HBV, wt HBV, PMEA-R HBV, and 3TC+PMEA-R HBV in transiently transfected Huh7 cells, with IC50s of 8 ± 3.8, 9 ± 2.5, 13 ± 3.4, and 15 ± 6.8 μM, respectively [1]. Lagociclovir (0-100 μM; 6 days) also inhibits the replication of HBV wild-type and drug-resistant mutants in transiently transfected Huh7 cells [2]. |
| In vivo | Anti-HBV compound Oral administration of MIV-210 (20 or 60 mg/kg; body weight/day) induced a rapid virological response in chronically infected woodchucks, reducing serum WHV DNA levels by 4.75 log10 and 5.72 log10, respectively, in 2 weeks. MIV-210 at 20 or 60 mg/kg/day reduced the liver WHV DNA load 200- to 2,500-fold from pretreatment levels and, importantly, led to a 2.0 log10 drop in the hepatic content of WHV covalently closed circular DNA. Further, a daily dose of 10 mg/kg decreased the serum WHV load 400-fold after 4 weeks of treatment, and a dose of 5 mg/kg/day was sufficient to maintain this antiviral effect during the following 6-week period.[1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 25 mg/mL (92.86 mM)
|
| Keywords | MIV210 | Lagociclovir | MIV 210 |
| Inhibitors Related | Doxorubicin hydrochloride | Osthole | RO8191 | Cetylpyridinium Chloride | Tenofovir Disoproxil Fumarate | Thiamine hydrochloride | 4,5-Dicaffeoylquinic acid | Vebicorvir | 4-Hydroxyacetophenone | Telbivudine | Tenofovir | Bifendate |
| Related Compound Libraries | Bioactive Compound Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | Clinical Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:142494-12-0
$195.00 / 1mg
-
CAS:63632-58-6
$195.00 / 1mg
-
CAS:59981-63-4
$55.00 / 50mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$2580.00/50mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-11-19 |
United States